Wilk Technologies Ltd

Wilk Technologies Ltd (Hebrew: וילק טכנולוגיות בע"מ), formerly known as BioMilk Ltd, is an Israeli publicly traded science and technology company focused on the development of cultivated milk components derived from mammary gland and breast epithelial cells. The company's scientific work is rooted in intellectual property originating from research conducted at the Faculty of Agriculture of the Hebrew University of Jerusalem by Prof. Nurit Argov-Argaman, combined with IP developed in-house. To commercialize this research, the company entered into an agreement with Yissum, the technology transfer company of the Hebrew University of Jerusalem. The company's history traces back to an entity called Fantasy Network Ltd, which until 2020 was engaged in investments in various fields. In October 2020, that company signed a merger agreement with BioMilk Technologies Ltd, a company developing cultivated milk, and this field became its primary activity as it separated from its previous lines of business. On 2 March 2021 the company changed its name to BioMilk Ltd, and on 11 November 2021 it changed its name to its current form, Wilk Technologies Ltd. The company's shares are listed on the Tel Aviv Stock Exchange. Wilk's R&D focuses on producing cultivated milk components, particularly human milk components, using immortalized human epithelial cells originating from breast tissue that act as producer cells secreting milk components, including milk fat. In nature, the fat secreted in mother's milk is wrapped in a unique envelope formed within the epithelial cells of the mammary gland, preserving its biological efficacy for the health of the fed infant — from maintaining intestinal wall integrity and preventing inflammation to the development of neuro-nervous systems in the brain. The company's scientific breakthrough is twofold: developing milk components from breast or cattle milk cells using technology that produces cell division and proliferation, intended for foods with important nutritional values including infant food; and developing immortal cells that are not limited in the number of cell divisions like normal cells, and therefore have mass-production potential enabling industrial-scale production volumes without dependence on the laboratory. From mid-January 2025, Dr. Ezra Ella, who had previously served as the company's Head of Innovation, took the role of CEO. Dr. Ella has led a commercialization move that includes promoting rapid market entry of products based on knowledge accumulated at Wilk and collaborations with other companies. Since the start of this move, the company has presented collaborations in the fields of cosmetics, food, and mother-and-child. On 30 July 2025 the company announced success in producing its first cosmetic product based on Wilk knowledge and receiving a formulation for a serum at the Tzalion plants, according to a stock exchange announcement. The company's CEO is Tomer Eizen and its Chief Scientist is Prof. Nurit Argov-Argaman.

Wilk Technologies Ltd traces its origins to an entity named Fantasy Network Ltd, which until 2020 was engaged in investments in various fields. In October 2020, Fantasy Network signed a merger agreement with BioMilk Technologies Ltd, a company developing cultivated milk, and this field became its primary activity as it separated from its previous lines of business. On 2 March 2021 the company changed its name to BioMilk Ltd, and on 11 November 2021 it changed its name to its current form, Wilk Technologies Ltd. The company is publicly traded on the Tel Aviv Stock Exchange. The company's scientific foundation rests on intellectual property that is the product of commercializing research conducted at the Faculty of Agriculture of the Hebrew University of Jerusalem by Dr. Nurit Argov-Argaman, together with intellectual property developed within the company. To turn the research into a commercial venture, the company entered into an agreement with Yissum, the technology transfer company of the Hebrew University of Jerusalem. Wilk's R&D is dedicated to scientific research and development of technologies for producing cultivated milk, based on mammary gland and breast epithelial cells. In nature, the fat secreted in mother's milk is wrapped in a unique envelope formed within the epithelial cells of the mammary gland, preserving its biological efficacy important for the health of the fed infant — from maintaining intestinal wall integrity, through preventing inflammation, to the development of neuro-nervous systems in the brain. The company's development team works on unique methods and analyses at the forefront of food technology for producing cultivated milk components in general and human milk components in particular. The team achieved a significant scientific breakthrough in growing immortalized human epithelial cells originating from breast tissue, whose role is to serve as producer cells secreting milk components, including milk fat. The scientific breakthrough is divided into two parts. First, the development of milk components from breast or cattle milk cells using technology that produces cell division and proliferation — a development intended for the production of foods with important nutritional values, including infant food. Second, the development of immortal cells that are not limited in the number of cell divisions like normal cells, and therefore have mass-production potential enabling industrial-scale production volumes without dependence on the laboratory. From mid-January 2025, Dr. Ezra Ella, who had previously served as the company's Head of Innovation, took the role of CEO. Dr. Ella has led a commercialization move that includes promoting rapid market entry of products based on knowledge accumulated at Wilk and collaborations with other companies. Since the start of this move, the company has presented collaborations in the fields of cosmetics, food, and mother-and-child. On 30 July 2025 the company announced success in producing its first cosmetic product based on Wilk knowledge and receiving a formulation for a serum at the Tzalion plants, according to a stock exchange announcement. The company's CEO is Tomer Eizen and its Chief Scientist is Prof. Nurit Argov-Argaman.

• Fantasy Network Ltd signed a merger agreement with BioMilk Technologies Ltd, making cultivated milk its primary activity.

• Company changed its name to BioMilk Ltd.

• Company changed its name to Wilk Technologies Ltd.

• Dr. Ezra Ella took the role of CEO, leading a commercialization move.

• Company announced success in producing its first cosmetic product based on Wilk knowledge and receiving a serum formulation at the Tzalion plants.

Food-tech and biotechnology company commercializing cultivated milk components for nutrition, infant food, and adjacent cosmetics applications.

• Cultivated milk components

  Milk components produced from breast or cattle milk cells using cell division and proliferation technology.

• Human milk fat components

  Milk fat components secreted by immortalized human epithelial cells originating from breast tissue.

• Cosmetic serum

  First cosmetic product based on Wilk knowledge, with a formulation received at the Tzalion plants.

1. 1Wilk Technologies Ltd on Wikidatawikidata.org
2. 2וילק טכנולוגיות – Wikipedia (Hebrew)he.wikipedia.org